MedTrace Logo

A Single Dose Pharmacokinetics (PK) Study of GSK2434735 in Healthy Male Volunteers

NCT01563042 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2017-06-20

No results posted yet for this study

Summary

An exploratory First Time in Human (FTIH) study investigating the pharmacokinetics, immunogenicity, safety and tolerability of GSK2434735 administered as a single low dose in healthy male subjects

Conditions

Interventions

DRUG

Intravenous (IV) single dose

GSK2434735 administered as a single intervenous dose at the beginning of the study

DRUG

Subcutaneous (SC) single dose

GSK2434735 administered as a single subcutaneous dose at the beginning of the study

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-02-13
Primary Completion
2012-05-23
Completion
2012-05-23

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01563042 on ClinicalTrials.gov